VERTEX PHARMACEUTICALS THIRD QUARTER 2026 EARNINGS CALL - CRINETICS PHARMACEUTICALS INC

Explicit Guidance:

• FY2026 total revenue raised to $13.15 billion – $13.5 billion (prior range: $13.1–$13.2 billion), driven by ~$40–$50 million contribution from Krenetics and underlying business growth.
• FY2026 non-GAAP gross margin expected slightly below 86%.
• FY2026 non-GAAP operating expenses revised to ~$6.0 billion (prior: $5.65–$5.75 billion), reflecting ~$250 million for Krenetics' integration and commercial spend.
• FY2026 non-GAAP effective tax rate expected 19.5% – 20.5%.
• FY2026 non-operating costs (Krenetics financing) expected ~$105 million; interest income projected ~$60 million lower YoY due to cash deployment.
• Full-year 2026 non-CF revenue target maintained: > $500 million (Casgevi + Jernavix), with ~$40 million added by Krenetics.
• FY2026 foreign exchange benefit expected ~150 basis points.
• FY2027 Palsonify revenue projected at ~$60 million for the first three quarters.
• FY2027 Jernavix gross-to-net expected to stabilize at 50–60% following the mid-year 2027 sunset of the Patient Support Program (PSP).

Business-Segment Outlook:

• Cystic Fibrosis (CF): Oliftrac (Upftrac) expected to treat up to 95% of CF population; global revenue growth driven by label expansions (rare mutations, ages 2–5), geographic penetration (10% CC growth in U.S., 12% outside U.S.), and survival benefits. Next-gen correctors (VX828, VX581, VX272) to be evaluated; next-gen 3.0 data (VX828) shows 6.6–9.4 mmol/L sweat chloride reduction vs. Trikafta; pivotal decision for the best-in-class molecule expected after data from VX581 and VX272 (expected next year).
• Hematology (Casgevi): Revenue > $500 million in FY2026; infusion timing visible for rest of 2026 and 2027; patient initiations >100/quarter for four consecutive quarters; potential to become a blockbuster.
• Pain (Jernavix): Targeting >3x prescriptions in 2026 vs. 2025; Phase III enrollment in painful diabetic peripheral neuropathy (DPN) to complete end of 2026; results to be shared mid-2027; gross-to-net normalization to 50–60% by mid-2027 as PSP is phased out.
• Renal (POVI/Anaxiplin): PDUFA date for POVI in IGAN on November 30; global launch ambition; KSA submission completed (7,000 patient opportunity); Amplitude (Anaxiplin) Phase 2-3 fully enrolled; interim analysis results expected early 2027; full dataset (2-year EGFR) to support global regulatory submissions.
• Rare Endocrinology (Palsonify): Launch trajectory strong; ~500 endocrinologists writing prescriptions; leading brand share >40% in initiation/switch; focus on expanding U.S. performance and preparing for international launches.
• T1D: Prioritization of VX017 (allogeneic, off-the-shelf islet cell therapy); dosing underway; pivotal development expected in 2027; hypoimmune islets and improved immunosuppression in serial innovation pipeline.

Market and Competitive Outlook:

• Pain Management: Jernavix already #1 prescribed branded oral analgesic in U.S. (1.6M+ patients treated); 750k+ prescriptions in Q3 2026 (+40% sequential); building a multi-billion dollar franchise via hospital/retail penetration.
• Renal: POVI positioned for best-in-class profile via low-volume, once-every-four-weeks auto-injector (96% patient preference in survey); competitors (B-cell modulators) expected to face monitoring hurdles; IgA nephropathy treatment landscape evolving with B-cell modulator uptake.
• CF: Oliftrac achieving sweat chloride levels in CF carrier range (no disease manifestation); next-gen 3.0 molecules aim to close residual gap in 95%+ coverage.
• Acromegaly: Palsonify capturing >40% market share; unmet need persists as only 40–50% of surgical patients achieve remission; oral once-daily differentiation vs. monthly injections.

Macro / Industry Outlook:

• FX: Full-year 2026 foreign exchange benefit expected at ~150 basis points.
• Regulatory: FDA agreement with Anaxiplin for GFR as primary endpoint for accelerated approval; global regulators may require two-year EGFR data (POVI) for non-U.S. filings.
• Pricing/Access: Securing broad Medicare Part D access (July 2026) drove one-time net revenue reset; PSP extended to 2027 to ensure patient access for non-covered plans.
• Manufacturing: POVI manufacturing confirmed via same partner through Phase 3 and PDUFA; continuous manufacturing for biologics (POVI) reviewed by FDA with no anticipated hurdles.

Strategic Initiatives:

• Krenetics Integration: Acquisition closed September; integration underway; $60 million in Q3 operating/integration costs; $250 million full-year OpEx impact; focus on commercial, clinical, and preclinical acceleration.
• Pipeline Advancement: VX017 (T1D) prioritized; Anaxiplin (AMKD) interim analysis expected early 2027; DPN Phase III results mid-2027; DM1 (VX670) interim results end of 2026; GME (VX670) proof-of-concept data H1 2027.
• Acquisitions/Partnerships: $28 million upfront payment for Abcelera BD agreement; strategic focus on external innovation and late-stage pipeline investment.
• Capital Deployment: $120 million share repurchases in Q3 (250k shares); $921 million YTD; priority on innovation and buybacks; $4.5 billion term loans (4.8% interest) to fund Krenetics.

Risks and Headwinds to Outlook:

• Regulatory: Pending FDA decisions on POVI (IGAN) and Anaxiplin (AMKD); potential citizen petitions (e.g., IgG monitoring for POVI) could impact label requirements.
• Commercial Execution: Jernavix PSP sunset (mid-2027) may temporarily impact gross-to-net; patient infusions for Casgevi subject to timing/seasonality (Q4).
• Clinical: Next-gen CF correctors (VX828, VX581, VX272) require comparative data before pivotal advancement; failure in Phase III DPN or AMKD trials could delay timelines.
• Integration: Krenetics integration costs and potential delays in commercial ramp-up.
• Macro: FX fluctuations; changes in payer coverage or reimbursement policies.

Management Tone on the Future:

• Confidence: High degree of certainty in FY2026 revenue guidance; 100% ready for POVI launch; strong conviction in POVI's differentiation and commercial potential.
• Strategic Focus: Transitioning from CF-only to five commercial pillars (CF, Heme, Pain, Endocrinology, Renal); emphasis on revenue diversification and global expansion.
• Tone: Optimistic but cautious on clinical milestones (waiting for comparative data in CF 3.0); proactive on commercial execution (PSP extension to secure access); accelerating pipeline through Krenetics integration.
• Leadership: Charlie Wagner's final call as CFO; Jonathan Poole to assume CFO role January 1, 2027; transition viewed as seamless with strong continuity.

Miscellaneous:

• Leadership Changes: Charlie Wagner (CFO) moves to COO (solely); Jonathan Poole (SVP Finance) becomes CFO Jan 1, 2027.
• Financial Highlights: Q3 2026 non-GAAP EPS $4.76; Q3 2026 total revenue $3.3 billion CF (+8% YoY), $99M Heme (+30% seq), $58M Pain (+18% qoq), $24M Endo (Palsonify).
• Pipeline Milestones: PDUFA for POVI Nov 30; Anaxiplin interim analysis early 2027; DPN Phase III results mid-2027; DM1 interim end of 2026.
• R&D Spend: Q3 non-GAAP R&D $936 million (+9% YoY); Q3 non-GAAP SG&A $556 million (+51% YoY) driven by POVI, Anaxiplin, Jernavix, and Palsonify.
• Balance Sheet: $9.8 billion cash/investments post-Krenetics; $4.5 billion term loans; $2 million shares repurchased YTD.